Mastocytosis is a rare condition where the body produces too many mast cells—special white blood cells that normally help fight infections but can trigger continuous allergic-like reactions when they multiply out of control. Treatment aims to reduce uncomfortable symptoms like flushing, itching, and stomach problems, prevent dangerous allergic reactions, and in more severe forms, slow disease progression in affected organs. The approach depends heavily on whether the condition affects only the skin or has spread to internal organs, and whether symptoms are mild or life-disrupting.

How Treatment Helps People with Mastocytosis

Living with mastocytosis means managing a body that overreacts to everyday situations. The main goal of treatment is not to cure the disease, but to help people live more comfortably and safely. Healthcare providers focus on controlling the release of histamine and other chemicals from mast cells, which are responsible for most symptoms. Histamine is the same substance released during allergic reactions, causing skin redness, swelling, itching, and in severe cases, dangerous drops in blood pressure.^[1]

Treatment strategies differ significantly depending on which type of mastocytosis someone has. Cutaneous mastocytosis, where abnormal mast cells gather only in the skin, is more common in children and often improves with age. Most children with this form experience relief as they grow, and many see their symptoms disappear completely by adolescence. Systemic mastocytosis, on the other hand, typically affects adults and involves mast cells building up in bone marrow, digestive organs, liver, spleen, or other body tissues. This form requires more comprehensive management because it can affect how organs function.^[2]

The treatment approach recognizes that each person’s experience with mastocytosis is unique. Some people have mild symptoms that barely interfere with daily life, while others experience severe, unpredictable reactions that can be frightening. Medical societies have established guidelines for standard treatments, but researchers continue exploring new therapies through clinical trials. These investigational treatments offer hope for people whose symptoms don’t respond well to currently available options.^[3]

Standard Treatment Approaches

The foundation of mastocytosis treatment involves medications that block the effects of histamine and other chemicals released by mast cells. These are called anti-mediator drugs because they work against the mediators—the chemical messengers that cause symptoms. The most commonly prescribed medications are antihistamines, which come in two main types: H1 blockers and H2 blockers. Each type targets different receptors in the body where histamine acts.^[5]

H1 antihistamines help control itching, flushing, skin redness, and hives. Doctors often recommend newer, non-sedating antihistamines like cetirizine or desloratadine for daytime use, since these don’t cause drowsiness. For nighttime, older antihistamines like diphenhydramine or hydroxyzine may be suggested because their mild sedating effect can help patients sleep despite itching. H2 antihistamines work differently—they reduce stomach acid production. This is particularly important for people with systemic mastocytosis who have too many mast cells in their digestive system, which can cause excessive stomach acid, ulcers, abdominal pain, and diarrhea. Common H2 blockers include ranitidine and famotidine.^[10]

Another important medication in the standard treatment toolkit is cromolyn sodium (sometimes called cromoglicate). This is a mast cell stabilizer, meaning it helps prevent mast cells from releasing their chemicals in the first place. When taken orally, cromolyn sodium can provide relief from abdominal pain, diarrhea, and other digestive symptoms. Some patients also report that it helps with brain fog and difficulty concentrating. The medication needs to be taken regularly to build up effectiveness, and it works best when taken before meals.^[5]

For people with cutaneous mastocytosis who have bothersome skin lesions, doctors may prescribe topical treatments. Corticosteroid creams (steroid creams) can be applied directly to affected skin areas for short periods. These powerful anti-inflammatory medications reduce the number of mast cells in the skin and calm the inflammatory response. However, they must be used carefully and only for limited time periods because prolonged use can thin the skin, cause stretch marks, reduce skin pigmentation, and make skin bruise more easily. Doctors typically recommend applying the cream only to lesions, not to healthy skin, to minimize side effects.^[10]

When skin symptoms are particularly severe and don’t respond to topical creams or antihistamines, doctors may suggest phototherapy. This involves exposing the skin to controlled amounts of ultraviolet light. The most common type used for mastocytosis is called PUVA therapy, which combines a light-sensitizing medication called psoralen with ultraviolet A (UVA) light exposure. PUVA can reduce itching and may cause skin lesions to fade. However, patients can only receive a limited number of PUVA sessions throughout their lifetime—around 150 treatments total—because excessive exposure increases the long-term risk of skin cancer.^[10]

In certain situations, doctors may prescribe oral corticosteroids (steroid tablets) for short courses. These are reserved for severe symptoms that don’t respond to other treatments, such as intense bone pain, severe skin involvement that covers large body areas, or to help prevent anaphylaxis in high-risk situations. Short-term use of oral steroids may cause increased appetite, weight gain, difficulty sleeping, fluid retention, and mood changes including irritability or anxiety. Because of these side effects and other risks with long-term use, doctors prescribe oral corticosteroids only when necessary and for the shortest effective duration.^[10]

For patients with systemic mastocytosis who develop weakened bones—a condition called osteoporosis that occurs when mast cells interfere with normal bone structure—doctors prescribe bisphosphonates. These medications slow down the breakdown of bone while allowing new bone formation to continue, which improves bone density and reduces fracture risk. Patients may also receive calcium supplements alongside bisphosphonates, as calcium is essential for building strong bones. This combination helps protect the skeleton from damage caused by abnormal mast cell activity in bone marrow.^[10]

Some patients find relief from additional medications depending on their specific symptoms. Proton pump inhibitors offer another option for reducing stomach acid beyond H2 blockers. Leukotriene antagonists like montelukast or zafirlukast, which are commonly used for asthma, may help some people with mastocytosis. When flushing remains a problem despite antihistamines, doctors sometimes prescribe low-dose aspirin, though this must be done carefully as some patients react badly to aspirin. For diarrhea that doesn’t respond to cromolyn or antihistamines, anticholinergic medications may provide relief.^[14]

Treatment duration for mastocytosis is typically long-term and often lifelong, particularly for systemic mastocytosis in adults. The condition requires ongoing management rather than a fixed treatment course. Patients usually need to take their anti-mediator medications continuously, not just when symptoms appear, because consistent medication levels help prevent symptoms from developing in the first place. Many people feel better because of their medications and might be tempted to stop when symptoms improve, but doctors strongly advise against stopping treatment without medical guidance, as symptoms will likely return.^[16]

Advanced Treatments Being Studied in Clinical Trials

Beyond standard symptom management, researchers are testing more targeted therapies that aim to reduce the number of abnormal mast cells in the body. These treatments are particularly important for people with aggressive forms of systemic mastocytosis where organs are affected and standard medications aren’t enough. Most of these experimental therapies work by targeting a specific genetic mutation found in mastocytosis cells.^[6]

The majority of adults with systemic mastocytosis—about 90%—have a mutation in a gene called KIT. This gene normally controls how mast cells grow and multiply. The mutation, most commonly called KIT D816V, acts like a switch that’s stuck in the “on” position. It tells mast cells to keep growing and dividing without stopping, even when the body doesn’t need more mast cells. This uncontrolled growth is the root cause of mastocytosis. Scientists have developed drugs that specifically target this faulty KIT protein, potentially offering a way to reduce the abnormal mast cell population.^[7]

One of the most studied drugs in clinical trials for systemic mastocytosis is midostaurin. This medication is a type of tyrosine kinase inhibitor—a drug that blocks enzymes involved in cell growth signals. Midostaurin can inhibit the activity of the mutated KIT protein, slowing down mast cell proliferation. Clinical trials have shown that midostaurin can reduce symptoms and decrease the burden of mast cells in patients with advanced systemic mastocytosis. Some patients experienced significant improvement in quality of life, with better energy levels, less abdominal discomfort, and reduced skin symptoms. The medication has been studied in Phase II and Phase III trials, which test both how well it works and how it compares to other treatments.^[6]

Another promising drug being investigated is avapritinib. This is a more selective KIT inhibitor, designed specifically to target the D816V mutation. Because it’s more selective, researchers hope it might work better with fewer side effects than less selective drugs. Early clinical trials called EXPLORER and PATHFINDER have tested avapritinib in patients with advanced systemic mastocytosis. Results from these trials showed that many patients experienced major reductions in mast cell burden and rapid improvement in symptoms. Some people saw their symptoms improve within weeks of starting treatment. The studies demonstrated that avapritinib could lead to remission—a state where the disease is no longer detectable or causing significant problems—in some patients with advanced disease.^[6]

For patients whose disease doesn’t respond to first-line KIT inhibitors or who have progressed to very aggressive forms, researchers are testing other cytoreductive agents—medications that reduce the number of disease cells. Interferon alpha is one such medication, originally developed for cancer treatment. Although scientists don’t fully understand why, interferon alpha appears to reduce mast cell production in bone marrow. It’s given by injection and patients often experience flu-like symptoms when starting the medication, including chills, fever, and joint pain. These side effects typically improve as the body adjusts to the treatment. Interferon alpha has been tested in patients with aggressive mastocytosis who needed more intensive therapy.^[10]

Another medication being studied is imatinib. This drug is well-known for treating certain types of leukemia, and it also blocks KIT signaling. However, imatinib doesn’t work as well in mastocytosis patients with the D816V mutation, which is the most common form. It may be more helpful for the smaller number of patients who have different KIT mutations or no KIT mutation at all. Trials have explored whether imatinib might benefit select groups of mastocytosis patients whose disease has specific genetic characteristics.^[10]

An innovative approach being explored involves omalizumab, a medication that works differently from KIT inhibitors. Omalizumab is a monoclonal antibody—a laboratory-made protein that targets a specific part of the immune system. It binds to immunoglobulin E (IgE), preventing IgE from attaching to mast cells and triggering reactions. This medication is already approved for treating severe asthma and chronic hives. Researchers are testing whether it can help mastocytosis patients who experience frequent, severe anaphylaxis that doesn’t respond well to standard medications. Early reports suggest that some patients with recurrent anaphylaxis episodes experienced fewer severe reactions after starting omalizumab treatment.^[14]

Clinical trials for mastocytosis treatments follow a standard progression through three phases. Phase I trials focus primarily on safety, determining what dose of a new drug can be given safely and what side effects occur. These trials usually involve small numbers of patients. Phase II trials expand to larger groups and assess whether the drug actually works—does it reduce symptoms, decrease mast cell numbers, or improve organ function? Phase III trials are even larger studies that compare the new treatment to current standard treatments or placebo, providing stronger evidence about effectiveness and safety. Only after successful completion of Phase III trials can a medication be submitted for approval by regulatory authorities.^[8]

These clinical trials are conducted at medical centers around the world. In the United States, major research hospitals and cancer centers often participate in mastocytosis trials. European countries also have active research programs, and some studies recruit internationally. To participate in a clinical trial, patients typically need to meet specific eligibility criteria. This might include having a particular subtype of mastocytosis (like advanced systemic mastocytosis), having symptoms despite standard treatment, or having certain test results. Some trials exclude patients with other significant medical conditions. Patients interested in trials should discuss options with their specialist, who can help determine if any suitable studies are available and whether participation makes sense for their situation.^[6]

Early results from studies of KIT-targeting drugs have been encouraging. Patients in clinical trials of midostaurin and avapritinib showed improvements in multiple areas: blood tests measuring mast cell activity improved, bone marrow biopsies showed fewer mast cells, and importantly, patients reported feeling better. Quality of life measurements—which capture how symptoms affect daily functioning, energy, mood, and ability to do usual activities—improved significantly for many trial participants. The rapid onset of symptom relief with some of these drugs has been particularly notable, with some patients noticing improvement within the first few weeks of treatment.^[6]

Most Common Treatment Methods

• Antihistamine therapy
  • H1 antihistamines like cetirizine, desloratadine, diphenhydramine, or hydroxyzine to control itching, flushing, and skin reactions
  • H2 antihistamines like ranitidine or famotidine to reduce stomach acid and treat digestive symptoms
  • Often used in combination to block histamine effects throughout the body
  • Typically taken daily on a long-term basis rather than only when symptoms appear
• Mast cell stabilizers
  • Oral cromolyn sodium to prevent mast cells from releasing chemicals
  • Particularly helpful for abdominal pain, diarrhea, and other gastrointestinal symptoms
  • May also improve cognitive symptoms like brain fog and concentration difficulties
  • Requires regular dosing, often before meals, to maintain effectiveness
• Topical corticosteroids
  • Steroid creams applied directly to skin lesions in cutaneous mastocytosis
  • Used for short-term treatment to reduce inflammation and mast cell numbers in skin
  • Must be used carefully to avoid side effects like skin thinning and stretch marks
  • Applied only to affected areas rather than healthy skin
• Phototherapy
  • PUVA therapy combining psoralen medication with ultraviolet A light exposure
  • Can reduce itching and fade skin lesions when topical treatments aren’t sufficient
  • Limited to approximately 150 lifetime sessions due to cumulative skin cancer risk
  • Considered second-line therapy when antihistamines don’t provide adequate relief
• Bone protection therapy
  • Bisphosphonates to slow bone breakdown and improve bone density in systemic mastocytosis
  • Calcium supplements to support bone health
  • Helps prevent fractures in patients with mast cell-related osteoporosis
• Gastric acid suppression
  • H2 blockers to reduce excess stomach acid production
  • Proton pump inhibitors as alternative or additional therapy for digestive symptoms
  • Treats ulcers and stomach pain caused by high mast cell activity in digestive system
• Targeted therapy (in clinical development)
  • Midostaurin, a tyrosine kinase inhibitor targeting the mutated KIT protein
  • Avapritinib, a selective KIT D816V inhibitor showing promise in clinical trials
  • Used primarily for advanced systemic mastocytosis with organ involvement
  • Can reduce mast cell burden and rapidly improve symptoms in trial participants
• Emergency preparedness
  • Adrenaline auto-injectors (epinephrine pens) carried at all times for anaphylaxis treatment
  • Typically two auto-injectors recommended in case one dose is insufficient
  • Emergency medications including extra doses of antihistamines
  • Medical alert identification to inform emergency responders about the condition